Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-07-01 DOI:10.1186/s12885-025-14446-9

Zhao-Dan Ye, Meng-Chen Song, Al-Kalei Ama, Li Zhuang, Yan Zhang, Sheng-Li Ye, He-Miao Shi, Si-Yi Zhong, Dan Zhu, Guo-Hong Cao, Jing-Feng Zhang

{"title":"Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study.","authors":"Zhao-Dan Ye, Meng-Chen Song, Al-Kalei Ama, Li Zhuang, Yan Zhang, Sheng-Li Ye, He-Miao Shi, Si-Yi Zhong, Dan Zhu, Guo-Hong Cao, Jing-Feng Zhang","doi":"10.1186/s12885-025-14446-9","DOIUrl":null,"url":null,"abstract":"Background: Tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains a significant challenge. This study systematically evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) for post-LT tumor recurrence.Methods: This retrospective study included 78 patients with recurrent intrahepatic HCC after LT. Seventy patients received TACE in combination with either sorafenib or lenvatinib, followed by regorafenib. Outcomes evaluated included time to progression (TTP), post-recurrence survival (PRS), post-transplantation survival (PTS), objective response rate (ORR), and adverse events (AEs).Results: The median TTP for recurrent intrahepatic HCC with combination therapy was 6 months (95% CI: 3.685-8.315), while the median PRS and PTS were 16 months (95% CI: 13.049-18.951) and 25 months (95% CI: 20.447-29.553), respectively. The ORR for intrahepatic tumors was 71.4%. AEs, including post-embolization syndrome and myelosuppression, were manageable.Conclusion: TACE combined with TKIs has good efficacy and safety in the treatment of HCC recurrence post-LT and is expected to prolong survival.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1049"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210462/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14446-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC) remains a significant challenge. This study systematically evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) for post-LT tumor recurrence.

Methods: This retrospective study included 78 patients with recurrent intrahepatic HCC after LT. Seventy patients received TACE in combination with either sorafenib or lenvatinib, followed by regorafenib. Outcomes evaluated included time to progression (TTP), post-recurrence survival (PRS), post-transplantation survival (PTS), objective response rate (ORR), and adverse events (AEs).

Results: The median TTP for recurrent intrahepatic HCC with combination therapy was 6 months (95% CI: 3.685-8.315), while the median PRS and PTS were 16 months (95% CI: 13.049-18.951) and 25 months (95% CI: 20.447-29.553), respectively. The ORR for intrahepatic tumors was 71.4%. AEs, including post-embolization syndrome and myelosuppression, were manageable.

Conclusion: TACE combined with TKIs has good efficacy and safety in the treatment of HCC recurrence post-LT and is expected to prolong survival.

查看原文本刊更多论文

tace联合索拉非尼或lenvatinib后regorafenib治疗肝移植后复发性肝细胞癌的预后影响：一项回顾性研究。

背景：肝细胞癌（HCC）的肝移植术后肿瘤复发仍然是一个重大挑战。本研究系统评价了经动脉化疗栓塞（TACE）联合酪氨酸激酶抑制剂（TKIs）治疗lt后肿瘤复发的疗效和安全性。方法：本回顾性研究纳入78例lt后复发性肝内HCC患者，其中70例患者接受TACE联合索拉非尼或lenvatinib，随后再加regorafenib。评估的结果包括进展时间（TTP）、复发后生存（PRS）、移植后生存（PTS）、客观缓解率（ORR）和不良事件（ae）。结果：联合治疗复发性肝内HCC的中位TTP为6个月（95% CI: 3.685-8.315），而中位PRS和PTS分别为16个月（95% CI: 13.049-18.951）和25个月（95% CI: 20.447-29.553）。肝内肿瘤的ORR为71.4%。包括栓塞后综合征和骨髓抑制在内的不良反应是可控的。结论：TACE联合TKIs治疗肝移植后HCC复发疗效好，安全性好，有望延长生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.